Clinical trial
S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has…
NCT00410813 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00410813 |
|---|---|
| Title | S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone |
| Official title | Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone Metastasis Predominant Metastatic Breast Cancer |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Metastatic Cancer |
| Intervention type | Drug |
| Interventions | dasatinib |
| Enrollment | 85 |
| Start date | Mar 1, 2007 |
| Primary completion | Jan 1, 2013 |
| Completion | Jan 1, 2014 |
| First posted | Dec 13, 2006 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: